



APIM THERAPEUTICS CLOSES 25 MNOK FINANCING ROUND.

The Board of APIM Therapeutics AS is pleased to announce that the Company has closed a Financing round raising 25 mNOK (3 m\$). Funds will be used to file a Clinical Trial Application (CTA) and start the clinical development program of APIM Therapeutics' anti-cancer lead compound, ATX-101.

Trondheim, December 1st, 2017 – APIM Therapeutics is an early stage therapeutic company based on ground breaking research by Prof. Marit Otterlei and co-workers (Norwegian University of Science and Technology, NTNU, Trondheim, Norway). The company is pursuing a novel approach for enhancing the efficacy of several currently used cancer therapies on multiple cancer indications. Specifically, APIM Therapeutics focuses on peptide drugs targeting PCNA (Proliferating Cell Nuclear Antigen), an emerging cancer drug target implicated in the regulation of cellular responses to cellular stress and tumor evasion from therapy. The company's lead drug candidate, ATX-101, has shown convincing anti-cancer activity in several blood and solid tumor cancer models in preclinical assays *in vitro* and *in vivo*.

APIM Therapeutics will file a CTA during H1 2018 and is planning to perform a Phase 1 study in advanced cancer patients ("all-comers") with ATX-101.

The largest part of the investment is provided by new investors Bergens forskningsstiftelse and Investinor AS and current lead investors Sarsia Seed AS and NIK III AS. Seven other shareholders including two new investors also participated in this round.

Kostas Alevizopoulos, CEO of APIM Therapeutics: *"We are delighted to have secured this funding in APIM Therapeutics which will allow us to take our novel therapeutic concept into first-in-man clinical trials".*

Investment Director Ann-Tove Kongsnes is head of the health and life sciences investment area at Investinor. She sees a large commercial potential in the biopharma company: *"APIM Therapeutics' novel approach offers a unique drug combination strategy to overcome treatment resistance. This first-in-class drug is expected to provide novel therapeutic options for the benefit of cancer patients, and addresses a huge market opportunity. It will be a great addition to Investinor's existing portfolio of biopharma companies".*

Erlend Skagseth, Managing Partner at Sarsia Seed and Chairman of APIM Therapeutics AS: *"Sarsia Seed is pleased to welcome Bergens forskningsstiftelse and Investinor AS onboard as strategic co-investment partners. Their equal enthusiasm for the company and its exceptional offering further consolidates our belief in APIM Therapeutics".*

For further information, please contact:

APIM Therapeutics AS
Kostas Alevizopoulos, CEO
Tel: +47 73 49 4002
e-mail: kalevizo@apimtherapeutics.com
www.apimtherapeutics.com